Global Drugs of Abuse Testing

Drugs of Abuse Testing Comprehensive Study by Type (Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers), Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices), Consumables), Application (Hospitals, Diagnostics Laboratories, Forensic Laboratories, Others), Sample Type (Urine, Oral Fluid, Blood, Breath, Hair, Others (Sweat) Players and Region - Global Market Outlook to 2030

Drugs of Abuse Testing Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Drugs of Abuse Testing Market Scope
Drugs of Abuse Testing is a method to detect the drugs present in a human body with the help of saliva, urine, blood, and sweat. This testing compromise of devices by which we can check or measure the intake of drugs in a human body and can be conducted at home or in laboratories. According to the United Nations Office on Drugs and Crime 246 million people in the age group from 15 to 64 use drugs and according to a National Survey, 9.8 million people across the globe suffer from mental illness due to the consumption of high drugs. Drugs that are majorly causing the addiction are cocaine, heroin, and marijuana among others. Increasing consumption of drugs by adults coupled with rising illness due to the consumption of drugs is driving the market for drug abuse testing.

AttributesDetails
Study Period2018-2030
Base Year2023
High Growth MarketAsia-Pacific
Largest MarketNorth America
UnitValue (USD Million)
Key Companies ProfiledF. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Drägerwerk AG & Co. KGaA (Germany), Laboratory Corporation of America Holdings (United States), Siemens Healthineers (Germany), Abbott Laboratories (United States), Danaher Corporation (Beckman Coulter, Inc.) (United States), Express Diagnostics International Inc. (United States), Shimadzu Corporation. (Japan) and Quest Diagnostics (United States)
CAGR%


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Drugs of Abuse Testing market throughout the predicted period.

F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (United States), Drägerwerk AG & Co. KGaA (Germany), Laboratory Corporation of America Holdings (United States), Siemens Healthineers (Germany), Abbott Laboratories (United States), Danaher Corporation (Beckman Coulter, Inc.) (United States), Express Diagnostics International Inc. (United States), Shimadzu Corporation. (Japan) and Quest Diagnostics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Psychemedics Corporation (United States), Bio-Rad Laboratories, Inc (United States) and Sonic Healthcare (Australia).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Drugs of Abuse Testing market by Type , by Application (Hospitals, Diagnostics Laboratories, Forensic Laboratories and Others) and Region with country level break-up.

On the basis of geography, the market of Drugs of Abuse Testing has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In October 2023, Quest Diagnostics partners with Altai Sciences, this partnership combines Quest's extensive testing facilities with Altai's expertise in developing new Drug Abuse Testing technologies.
In July 2023, Eurofins Scientific acquires Bio-Quant, Inc., this acquisition strengthens Eurofins' position in North America's Drug Abuse Testing market, particularly in workplace and pain management testing.
FDA does not review drugs of abuse tests intended for employment and insurance testing provided they include a statement in their labeling that the device is intended solely for use in employment and insurance testing, and does not include test systems intended for Federal drug testing programs (e.g., programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military)

Influencing Trend:
Adoption of Drug Testing At the Workplace and Highly Usage of Drug Abuse Tests For Legal and Medical Purposes

Market Growth Drivers:
Increasing More Consumption of Drugs among Adults across Globe, Rising Advancements in Technology of Analyzers, Increasing Availability of Forbidden Drugs and Increase in Impact of Drug and Alcohol Abuse on Public Health

Challenges:
Concerns Related To the Inability to Detect Low-Dose Designer Drugs and Issue Related To Accuracy and Specificity Concerns Related To Breathalyzers

Restraints:
Lack of Awareness Regarding the Availability of Advanced Drug Testing Devices, High Prices Related To Drug Testing and Lack of a Global Standard Definition of a Problem Drug User

Opportunities:
Increasing Number of Toxicological Laboratories in both Developed and Developing Countries, Rising Demand for Drug Abuse Testing Among Private Employers and Growing Emphasis on Work Place Screening Among the Urban Populations

Key Target Audience
Drug of abuse testing companies, Drug of abuse testing reagent Manufacturers, Hospitals and Clinics, Diagnostics Centers, National Organizations & Government Organizations, Academic research institutes and Government institutes

Report Objectives / Segmentation Covered

By Type
  • Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers)
  • Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices)
  • Consumables
By Application
  • Hospitals
  • Diagnostics Laboratories
  • Forensic Laboratories
  • Others
By Sample Type
  • Urine
  • Oral Fluid
  • Blood
  • Breath
  • Hair
  • Others (Sweat

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing More Consumption of Drugs among Adults across Globe
      • 3.2.2. Rising Advancements in Technology of Analyzers
      • 3.2.3. Increasing Availability of Forbidden Drugs
      • 3.2.4. Increase in Impact of Drug and Alcohol Abuse on Public Health
    • 3.3. Market Challenges
      • 3.3.1. Concerns Related To the Inability to Detect Low-Dose Designer Drugs
      • 3.3.2. Issue Related To Accuracy and Specificity Concerns Related To Breathalyzers
    • 3.4. Market Trends
      • 3.4.1. Adoption of Drug Testing At the Workplace
      • 3.4.2. Highly Usage of Drug Abuse Tests For Legal and Medical Purposes
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drugs of Abuse Testing, by Type, Application, Sample Type and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Drugs of Abuse Testing (Value)
      • 5.2.1. Global Drugs of Abuse Testing by: Type (Value)
        • 5.2.1.1. Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers)
        • 5.2.1.2. Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices)
        • 5.2.1.3. Consumables
      • 5.2.2. Global Drugs of Abuse Testing by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Diagnostics Laboratories
        • 5.2.2.3. Forensic Laboratories
        • 5.2.2.4. Others
      • 5.2.3. Global Drugs of Abuse Testing by: Sample Type (Value)
        • 5.2.3.1. Urine
        • 5.2.3.2. Oral Fluid
        • 5.2.3.3. Blood
        • 5.2.3.4. Breath
        • 5.2.3.5. Hair
        • 5.2.3.6. Others (Sweat
      • 5.2.4. Global Drugs of Abuse Testing Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Drugs of Abuse Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Thermo Fisher Scientific Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Drägerwerk AG & Co. KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Laboratory Corporation of America Holdings (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Siemens Healthineers (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Abbott Laboratories (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Danaher Corporation (Beckman Coulter, Inc.) (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Express Diagnostics International Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Shimadzu Corporation. (Japan)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Quest Diagnostics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drugs of Abuse Testing Sale, by Type, Application, Sample Type and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Drugs of Abuse Testing (Value)
      • 7.2.1. Global Drugs of Abuse Testing by: Type (Value)
        • 7.2.1.1. Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers)
        • 7.2.1.2. Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices)
        • 7.2.1.3. Consumables
      • 7.2.2. Global Drugs of Abuse Testing by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Diagnostics Laboratories
        • 7.2.2.3. Forensic Laboratories
        • 7.2.2.4. Others
      • 7.2.3. Global Drugs of Abuse Testing by: Sample Type (Value)
        • 7.2.3.1. Urine
        • 7.2.3.2. Oral Fluid
        • 7.2.3.3. Blood
        • 7.2.3.4. Breath
        • 7.2.3.5. Hair
        • 7.2.3.6. Others (Sweat
      • 7.2.4. Global Drugs of Abuse Testing Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drugs of Abuse Testing: by Type(USD Million)
  • Table 2. Drugs of Abuse Testing Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers) , by Region USD Million (2018-2023)
  • Table 3. Drugs of Abuse Testing Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices) , by Region USD Million (2018-2023)
  • Table 4. Drugs of Abuse Testing Consumables , by Region USD Million (2018-2023)
  • Table 5. Drugs of Abuse Testing: by Application(USD Million)
  • Table 6. Drugs of Abuse Testing Hospitals , by Region USD Million (2018-2023)
  • Table 7. Drugs of Abuse Testing Diagnostics Laboratories , by Region USD Million (2018-2023)
  • Table 8. Drugs of Abuse Testing Forensic Laboratories , by Region USD Million (2018-2023)
  • Table 9. Drugs of Abuse Testing Others , by Region USD Million (2018-2023)
  • Table 10. Drugs of Abuse Testing: by Sample Type(USD Million)
  • Table 11. Drugs of Abuse Testing Urine , by Region USD Million (2018-2023)
  • Table 12. Drugs of Abuse Testing Oral Fluid , by Region USD Million (2018-2023)
  • Table 13. Drugs of Abuse Testing Blood , by Region USD Million (2018-2023)
  • Table 14. Drugs of Abuse Testing Breath , by Region USD Million (2018-2023)
  • Table 15. Drugs of Abuse Testing Hair , by Region USD Million (2018-2023)
  • Table 16. Drugs of Abuse Testing Others (Sweat , by Region USD Million (2018-2023)
  • Table 17. South America Drugs of Abuse Testing, by Country USD Million (2018-2023)
  • Table 18. South America Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 19. South America Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 20. South America Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 21. Brazil Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 22. Brazil Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 23. Brazil Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 24. Argentina Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 25. Argentina Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 26. Argentina Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 27. Rest of South America Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 28. Rest of South America Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 29. Rest of South America Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 30. Asia Pacific Drugs of Abuse Testing, by Country USD Million (2018-2023)
  • Table 31. Asia Pacific Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 32. Asia Pacific Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 33. Asia Pacific Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 34. China Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 35. China Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 36. China Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 37. Japan Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 38. Japan Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 39. Japan Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 40. India Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 41. India Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 42. India Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 43. South Korea Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 44. South Korea Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 45. South Korea Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 46. Taiwan Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 47. Taiwan Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 48. Taiwan Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 49. Australia Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 50. Australia Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 51. Australia Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 52. Rest of Asia-Pacific Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 53. Rest of Asia-Pacific Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 54. Rest of Asia-Pacific Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 55. Europe Drugs of Abuse Testing, by Country USD Million (2018-2023)
  • Table 56. Europe Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 57. Europe Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 58. Europe Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 59. Germany Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 60. Germany Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 61. Germany Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 62. France Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 63. France Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 64. France Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 65. Italy Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 66. Italy Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 67. Italy Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 68. United Kingdom Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 69. United Kingdom Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 70. United Kingdom Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 71. Netherlands Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 72. Netherlands Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 73. Netherlands Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 74. Rest of Europe Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 75. Rest of Europe Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 76. Rest of Europe Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 77. MEA Drugs of Abuse Testing, by Country USD Million (2018-2023)
  • Table 78. MEA Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 79. MEA Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 80. MEA Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 81. Middle East Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 82. Middle East Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 83. Middle East Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 84. Africa Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 85. Africa Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 86. Africa Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 87. North America Drugs of Abuse Testing, by Country USD Million (2018-2023)
  • Table 88. North America Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 89. North America Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 90. North America Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 91. United States Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 92. United States Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 93. United States Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 94. Canada Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 95. Canada Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 96. Canada Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 97. Mexico Drugs of Abuse Testing, by Type USD Million (2018-2023)
  • Table 98. Mexico Drugs of Abuse Testing, by Application USD Million (2018-2023)
  • Table 99. Mexico Drugs of Abuse Testing, by Sample Type USD Million (2018-2023)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Drugs of Abuse Testing: by Type(USD Million)
  • Table 111. Drugs of Abuse Testing Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers) , by Region USD Million (2025-2030)
  • Table 112. Drugs of Abuse Testing Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices) , by Region USD Million (2025-2030)
  • Table 113. Drugs of Abuse Testing Consumables , by Region USD Million (2025-2030)
  • Table 114. Drugs of Abuse Testing: by Application(USD Million)
  • Table 115. Drugs of Abuse Testing Hospitals , by Region USD Million (2025-2030)
  • Table 116. Drugs of Abuse Testing Diagnostics Laboratories , by Region USD Million (2025-2030)
  • Table 117. Drugs of Abuse Testing Forensic Laboratories , by Region USD Million (2025-2030)
  • Table 118. Drugs of Abuse Testing Others , by Region USD Million (2025-2030)
  • Table 119. Drugs of Abuse Testing: by Sample Type(USD Million)
  • Table 120. Drugs of Abuse Testing Urine , by Region USD Million (2025-2030)
  • Table 121. Drugs of Abuse Testing Oral Fluid , by Region USD Million (2025-2030)
  • Table 122. Drugs of Abuse Testing Blood , by Region USD Million (2025-2030)
  • Table 123. Drugs of Abuse Testing Breath , by Region USD Million (2025-2030)
  • Table 124. Drugs of Abuse Testing Hair , by Region USD Million (2025-2030)
  • Table 125. Drugs of Abuse Testing Others (Sweat , by Region USD Million (2025-2030)
  • Table 126. South America Drugs of Abuse Testing, by Country USD Million (2025-2030)
  • Table 127. South America Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 128. South America Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 129. South America Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 130. Brazil Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 131. Brazil Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 132. Brazil Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 133. Argentina Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 134. Argentina Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 135. Argentina Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 136. Rest of South America Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 137. Rest of South America Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 138. Rest of South America Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 139. Asia Pacific Drugs of Abuse Testing, by Country USD Million (2025-2030)
  • Table 140. Asia Pacific Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 141. Asia Pacific Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 142. Asia Pacific Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 143. China Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 144. China Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 145. China Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 146. Japan Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 147. Japan Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 148. Japan Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 149. India Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 150. India Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 151. India Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 152. South Korea Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 153. South Korea Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 154. South Korea Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 155. Taiwan Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 156. Taiwan Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 157. Taiwan Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 158. Australia Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 159. Australia Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 160. Australia Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 161. Rest of Asia-Pacific Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 162. Rest of Asia-Pacific Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 163. Rest of Asia-Pacific Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 164. Europe Drugs of Abuse Testing, by Country USD Million (2025-2030)
  • Table 165. Europe Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 166. Europe Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 167. Europe Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 168. Germany Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 169. Germany Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 170. Germany Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 171. France Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 172. France Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 173. France Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 174. Italy Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 175. Italy Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 176. Italy Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 177. United Kingdom Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 178. United Kingdom Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 179. United Kingdom Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 180. Netherlands Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 181. Netherlands Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 182. Netherlands Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 183. Rest of Europe Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 184. Rest of Europe Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 185. Rest of Europe Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 186. MEA Drugs of Abuse Testing, by Country USD Million (2025-2030)
  • Table 187. MEA Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 188. MEA Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 189. MEA Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 190. Middle East Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 191. Middle East Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 192. Middle East Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 193. Africa Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 194. Africa Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 195. Africa Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 196. North America Drugs of Abuse Testing, by Country USD Million (2025-2030)
  • Table 197. North America Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 198. North America Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 199. North America Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 200. United States Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 201. United States Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 202. United States Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 203. Canada Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 204. Canada Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 205. Canada Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 206. Mexico Drugs of Abuse Testing, by Type USD Million (2025-2030)
  • Table 207. Mexico Drugs of Abuse Testing, by Application USD Million (2025-2030)
  • Table 208. Mexico Drugs of Abuse Testing, by Sample Type USD Million (2025-2030)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drugs of Abuse Testing: by Type USD Million (2018-2023)
  • Figure 5. Global Drugs of Abuse Testing: by Application USD Million (2018-2023)
  • Figure 6. Global Drugs of Abuse Testing: by Sample Type USD Million (2018-2023)
  • Figure 7. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 8. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 9. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 10. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 11. North America Drugs of Abuse Testing Share (%), by Country
  • Figure 12. Global Drugs of Abuse Testing share by Players 2023 (%)
  • Figure 13. Global Drugs of Abuse Testing share by Players (Top 3) 2023(%)
  • Figure 14. Global Drugs of Abuse Testing share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 17. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2023
  • Figure 18. Thermo Fisher Scientific Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 19. Thermo Fisher Scientific Inc. (United States) Revenue: by Geography 2023
  • Figure 20. Drägerwerk AG & Co. KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 21. Drägerwerk AG & Co. KGaA (Germany) Revenue: by Geography 2023
  • Figure 22. Laboratory Corporation of America Holdings (United States) Revenue, Net Income and Gross profit
  • Figure 23. Laboratory Corporation of America Holdings (United States) Revenue: by Geography 2023
  • Figure 24. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 25. Siemens Healthineers (Germany) Revenue: by Geography 2023
  • Figure 26. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 27. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 28. Danaher Corporation (Beckman Coulter, Inc.) (United States) Revenue, Net Income and Gross profit
  • Figure 29. Danaher Corporation (Beckman Coulter, Inc.) (United States) Revenue: by Geography 2023
  • Figure 30. Express Diagnostics International Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Express Diagnostics International Inc. (United States) Revenue: by Geography 2023
  • Figure 32. Shimadzu Corporation. (Japan) Revenue, Net Income and Gross profit
  • Figure 33. Shimadzu Corporation. (Japan) Revenue: by Geography 2023
  • Figure 34. Quest Diagnostics (United States) Revenue, Net Income and Gross profit
  • Figure 35. Quest Diagnostics (United States) Revenue: by Geography 2023
  • Figure 36. Global Drugs of Abuse Testing: by Type USD Million (2025-2030)
  • Figure 37. Global Drugs of Abuse Testing: by Application USD Million (2025-2030)
  • Figure 38. Global Drugs of Abuse Testing: by Sample Type USD Million (2025-2030)
  • Figure 39. South America Drugs of Abuse Testing Share (%), by Country
  • Figure 40. Asia Pacific Drugs of Abuse Testing Share (%), by Country
  • Figure 41. Europe Drugs of Abuse Testing Share (%), by Country
  • Figure 42. MEA Drugs of Abuse Testing Share (%), by Country
  • Figure 43. North America Drugs of Abuse Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Thermo Fisher Scientific Inc. (United States)
  • Drägerwerk AG & Co. KGaA (Germany)
  • Laboratory Corporation of America Holdings (United States)
  • Siemens Healthineers (Germany)
  • Abbott Laboratories (United States)
  • Danaher Corporation (Beckman Coulter, Inc.) (United States)
  • Express Diagnostics International Inc. (United States)
  • Shimadzu Corporation. (Japan)
  • Quest Diagnostics (United States)
Additional players considered in the study are as follows:
Psychemedics Corporation (United States) , Bio-Rad Laboratories, Inc (United States) , Sonic Healthcare (Australia)
Select User Access Type

Key Highlights of Report


Jul 2024 245 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drugs of Abuse Testing Quantitative research analysis
Global Drugs of Abuse Testing Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Drugs of Abuse Testing Market are by type [Analyzers (Immunoassay Analyzers, Chromatographic Devices, Breath Analyzers), Rapid Testing Devices (Urine Testing Devices, Oral Fluid Testing Devices) and Consumables], by end use application [Hospitals, Diagnostics Laboratories, Forensic Laboratories and Others].
The Drugs of Abuse Testing Market is gaining popularity and expected to see strong valuation by 2030.
  • Increasing More Consumption of Drugs among Adults across Globe
  • Rising Advancements in Technology of Analyzers
  • Increasing Availability of Forbidden Drugs
  • Increase in Impact of Drug and Alcohol Abuse on Public Health

Know More About Global Drugs of Abuse Testing Report?

Have a Query? Click Here

Other Related Reports

Sterilization Monitoring Comprehensive Study by Type (Biological Indicators, Chemical Indicators), Application (Hospitals, Pharmaceutical, Biotechnology, and Medical Device Companies, Research and Ac...
$ 3800
Retail Clinics Comprehensive Study by Type (Hospital-owned Retail Clinics, Retail-owned Retail Clinics), Application (Clinical Chemistry & Immunoassay, Point of Care Diagnostics, Others), Distributio...
$ 3500
Dental Drug Comprehensive Study by Type (Injectable, Oral, Spray), Application (Drug stores, Retail pharmacies, Hospital pharmacies, Online stores) Players and Region - Global Market Outlook to 2026
$ 3500
Prostate Cancer Diagnostics Comprehensive Study by Type (Tumor Biomarker Tests, Imaging, Biopsy, Other), Treatment (Surveillance, Localized Therapy, Systemic Therapy, Others), Test Type (Preliminary ...
$ 3750
Brain Aneurysm Treatment Comprehensive Study by Type (Surgical Clipping, Endovascular Coiling, Flow diverters), Application (Hospitals, Clinics), Type (Unruptured Aneurysm, Ruptured Aneurysm) Players...
$ 3500
Membrane Filtration Systems Comprehensive Study by Type (Microfiltration (MF), Ultrafiltration (UF), Nanofiltration (NF), Reverse Osmosis (RO)), Application (Industrial Water And Wastewater Treatment...
$ 3450